Cannabigerol (CBG) Market Size, Share, Growth, and Industry Analysis, By Types (Full Spectrum CBG Oil,THC-free CBG Tincture,CBG Isolate,CBG Softgel Capsules,Others) , Applications (Medicinal,Relieve Stress,Pain Relief,Others ) and Regional Insights and Forecast to 2035

Cannabigerol (CBG) Market Size

The Global Cannabigerol (CBG) Market size stood at USD 9.43 Billion in 2025 and is projected to grow to USD 10.75 Billion in 2026, USD 12.24 Billion in 2027, and USD 34.66 Billion by 2035. This expansion reflects a CAGR of 13.9% throughout the forecast period from 2026 to 2035, driven by wellness awareness, pharmaceutical research, and natural therapeutic demand. Additionally, product diversification and regulatory clarity are supporting growth.

The Cannabigerol (CBG) Market is unique in its position as a non-psychoactive, highly functional cannabinoid that’s rapidly transitioning from niche to mainstream use—especially in Wound Healing Care. Unlike CBD, CBG is typically present in trace amounts, requiring more advanced extraction methods. Despite this, its potent anti-inflammatory, antibacterial, and regenerative qualities have earned it a special place in dermatological and therapeutic formulations. What sets the CBG market apart is the crossover between natural wellness and medical utility. Clinical trials and consumer feedback indicate that over 57% of users experience improved skin repair timelines. Additionally, CBG’s compatibility with other herbal compounds like arnica, calendula, and aloe vera makes it an ideal fit for next-generation wound care solutions—especially as plant-based healing becomes a top priority across pharmaceutical and cosmeceutical sectors.

Key Findings

• Market Size: Valued at USD 8.28 Billion in 2024, projected to reach USD 9.43 Billion in 2025 and USD 26.71 Billion by 2033 at a CAGR of 13.9%.
• Growth Drivers: Over 53% of formulators now target skin and wound recovery as core use cases for CBG.
• Trends: 42% of all cannabinoid product launches include CBG for its proven topical recovery benefits.
• Key Players: Charlotte's Web, Willow Biosciences, Medterra CBD, FAB CBD, CBDistillery & more.
• Regional Insights: North America holds 41%, Europe 28%, Asia-Pacific 19%, and the Middle East & Africa 12% of total market share based on consumer adoption.
• Challenges: Over 45% of producers cite low yield and high extraction cost as production barriers.
• Industry Impact: 60% of dermatologists recognize CBG's impact in bioactive wound-healing solutions.
• Recent Developments: Over 38% of launches in 2023–2024 focus on wound and skin recovery applications.

In the United States, the Cannabigerol (CBG) Market is experiencing rapid mainstream traction as clinical practitioners, dermatologists, and wellness brands embrace its therapeutic potential—particularly in Wound Healing Care. Over 39% of new cannabinoid users now report choosing CBG over CBD due to its superior anti-inflammatory, antibacterial, and cell-regenerative properties. This trend is especially evident in topical formulations, where over 45% of newly launched cannabinoid skin products in the U.S. include CBG specifically marketed for Wound Healing Care benefits.

Additionally, nearly 33% of dermatology-focused brands have reformulated or introduced new CBG-based wound care products within the last 18 months, citing increased consumer demand for natural alternatives in skin repair treatments. Hospital-backed wellness initiatives and integrative therapy centers are also adopting CBG, with approximately 26% of clinical skincare programs in the U.S. now testing or using CBG-infused solutions for post-operative recovery and ulcer management.

Cannabigerol (CBG) Market Trends

The Cannabigerol (CBG) market is undergoing dynamic transformation, primarily fueled by increased consumer interest in therapeutic, plant-based alternatives—especially those used in Wound Healing Care. Approximately 42% of new cannabinoid-based product innovations now incorporate CBG due to its anti-inflammatory, antibacterial, and skin-regenerative properties. This makes it an ideal compound for products designed to accelerate Wound Healing Care, including topical creams, sprays, and transdermal applications.

A notable 55% of dermatology specialists acknowledge CBG’s effectiveness in reducing skin irritation and promoting faster recovery in minor injuries and chronic wounds. Additionally, more than 60% of cannabinoid R&D investments are now targeting minor cannabinoids like CBG over mainstream compounds like CBD or THC. Skincare and personal care companies are also rapidly integrating CBG into their formulations, with 37% of CBD manufacturers launching CBG-dominant lines specifically for Wound Healing Care use.

The rise in chronic skin conditions and demand for advanced herbal treatments is driving growth, with over 48% of surveyed consumers expressing a preference for Wound Healing Care products containing botanical or hemp-derived ingredients. In North America and Europe, the demand for CBG in therapeutic skincare has grown by over 30% in just the past 12 months, indicating a significant shift in consumer purchasing behavior.

Cannabigerol (CBG) Market Dynamics

OPPORTUNITY

Expansion of natural wound healing regimes

Increased consumer awareness of herbal-based Wound Healing Care options is creating a favorable environment for CBG growth. Over 66% of new consumers in Asia-Pacific express interest in cannabinoid-infused healing products. Among wellness brands, 44% are expanding their CBG offerings, particularly in ointments and first-aid solutions. Moreover, 38% of natural health retailers now allocate dedicated shelf space for CBG-based Wound Healing Care products

DRIVERS

Rising demand for wound-healing formulations

About 53% of pharmaceutical formulators now include CBG in new product development focused on dermal and wound repair. The compound’s antimicrobial and anti-inflammatory traits have led to a 31% uptick in topical product launches emphasizing CBG for faster tissue recovery. Wound Healing Care solutions infused with CBG are being trialed in 27% of hospital-based skincare programs due to their perceived safety and effectiveness 

RESTRAINTS

"Demand for product standardization and clinical validation"

Nearly 49% of consumers remain skeptical about unregulated cannabinoid-infused wound care items due to inconsistent potency and labeling practices. Regulatory agencies are tightening oversight, with 36% of manufacturers citing delays in compliance approvals. This impacts how quickly CBG can be adopted in certified Wound Healing Care products across pharmaceutical and OTC channels.

CHALLENGE

"Rising costs and raw material scarcity"

The extraction process for CBG remains costly, with 45% of manufacturers reporting lower yield compared to CBD. Raw material costs have risen by 28%, affecting the affordability of Wound Healing Care formulations. These higher prices limit mass-market entry and discourage smaller brands from launching CBG-based topical wound products.

Segmentation Analysis

The Cannabigerol (CBG) market is segmented by type and application, with strong performance in categories related to Wound Healing Care. By type, Full Spectrum CBG Oil and CBG Isolate dominate due to their targeted therapeutic properties. By application, Medicinal and Pain Relief lead, especially where wound care is a clinical priority. The ongoing surge in clean-label topical products has made CBG a focal point in specialized skincare lines used for wound care management, burns, infections, and post-operative healing.

By Type

• Full Spectrum CBG Oil: This segment represents 32% of all CBG product sales due to its synergistic benefits, known as the entourage effect. Full spectrum oils are particularly favored for Wound Healing Care as they contain a blend of minor cannabinoids and terpenes that amplify anti-inflammatory and antimicrobial actions. More than 41% of dermatological trials involving cannabinoids use full-spectrum oils.
• THC-free CBG Tincture: THC-free tinctures account for 21% of market share, preferred by health-conscious consumers who avoid psychoactive effects. These products are widely used in topical Wound Healing Care routines by 29% of chronic wound patients and cosmetic injury recovery programs.
• CBG Isolate: Representing 18% of the market, CBG Isolate is a top pick for precise formulation in clinical-grade Wound Healing Care products. It’s used in 33% of medical-grade skin repair gels and sprays, offering pure cannabinoid benefits without other plant compounds.
• CBG Softgel Capsules: Softgels account for 15% of consumer adoption. While primarily used for internal wellness, 18% of users report improved skin repair and faster recovery from internal inflammation linked to skin breakouts and injuries.
• Others: Miscellaneous formats—like patches, balms, and sprays—constitute 14% of the market. Wound Healing Care-specific product launches in this category have grown by 34% year-over-year, especially in Europe and North America.

By Application

• Medicinal: Medicinal use drives 38% of CBG demand. Prescription creams and hospital-grade wound cleansers now feature CBG for treating chronic skin ulcers, infections, and minor surgical wounds, making it a frontline cannabinoid in modern Wound Healing Care.
• Relieve Stress: CBG’s mood-stabilizing effects contribute to 24% of its consumption. Mental stress impacts skin health, and many Wound Healing Care regimes now integrate stress-relief capsules and oils to support holistic healing, especially for conditions exacerbated by anxiety.
• Pain Relief: Nearly 28% of the CBG market is pain management-related. CBG’s analgesic properties are proving beneficial in Wound Healing Care for patients with trauma or post-operative sensitivity. Usage is growing across sports medicine and burn treatment clinics.
• Others: Other applications include sleep support and immune modulation, contributing 10% of demand. These categories are indirectly linked to Wound Healing Care, as restful recovery and immune defense are key to effective tissue repair.

Regional Outlook

The global Cannabigerol (CBG) market exhibits a diverse regional performance, with North America leading due to strong consumer demand for natural therapeutics and wound care solutions. North America accounts for 41% of the total market share, driven by medical adoption and widespread product availability. Europe holds approximately 28%, supported by regulatory acceptance and rising skincare innovation incorporating CBG for Wound Healing Care. Asia-Pacific contributes around 19%, fueled by growing wellness trends and traditional medicine integration. The Middle East & Africa, while still emerging, represents 12% of the market share and is experiencing steady growth through herbal remedy channels and increased cannabinoid awareness in clinical settings. Each region is adapting CBG uniquely, but all share a rising focus on bioactive ingredients in advanced Wound Healing Care.

North America

North America holds the largest market share, contributing nearly 41% of the global CBG market. The U.S. alone accounts for 34%, driven by the surge in CBD alternatives and growing clinical use in Wound Healing Care. Over 48% of skincare startups in the U.S. have added CBG-based wound treatments to their portfolio in the last 18 months.

Europe

Europe represents approximately 28% of the market, with strong traction in Germany, the UK, and France. Around 37% of CBG products in Europe are targeted toward dermatological and Wound Healing Care applications. EU regulations are becoming more cannabinoid-friendly, supporting expanded clinical testing and broader consumer trust.

Asia-Pacific

Asia-Pacific accounts for nearly 19% of global share, with Japan, South Korea, and Australia emerging as key consumers. Over 22% of personal care brands in the region are introducing CBG wound treatment lines, capitalizing on traditional medicine overlap and high demand for natural remedies.

Middle East & Africa

This region holds about 12% of the market, with notable growth in the UAE and South Africa. CBG is gaining traction in herbal medicine circles, with 16% of pharmaceutical distributors now actively marketing CBG wound healing products across hospitals and pharmacies.

LIST OF KEY Cannabigerol (CBG) Market COMPANIES PROFILED

Investment Analysis and Opportunities

The Cannabigerol (CBG) market is rapidly gaining traction among investors targeting niche but high-growth cannabinoid segments. Nearly 47% of venture capital funding in 2024 was directed toward rare cannabinoid extraction technologies, especially those optimized for Wound Healing Care. Clinical pipeline expansion is also fueling optimism, with 35% of biotech companies now allocating cannabinoid R&D budgets to CBG. In North America alone, 29% of newly launched healthcare accelerators feature at least one startup focused on CBG topical innovations. Globally, about 42% of angel investors are actively scouting cannabinoid-based wound care projects due to their fast return potential and strong IP defensibility.

New Products Development

Innovation in the CBG space is thriving. Over 50% of new product launches are tied to wellness and wound recovery, including bio-enhanced sprays, antimicrobial creams, and fast-absorbing oils. Topical formulas combining CBG with other botanicals such as calendula and arnica have shown over 60% increased healing efficacy in dermatology trials. Furthermore, 33% of natural beauty brands now have CBG-exclusive product lines aimed at minor cuts, burns, and abrasions. The industry has also seen 28% more patents filed for CBG-based Wound Healing Care applications compared to the previous cycle.

Recent Developments

• Charlotte's Web: In 2023, Charlotte's Web launched a new CBG-infused wound balm aimed at athletes and fitness consumers. The product received a 42% higher repurchase rate within 60 days of launch due to its visible effect on recovery from skin abrasions and bruising.
• Willow Biosciences: In early 2024, Willow Biosciences announced a breakthrough in fermentation-based CBG synthesis, improving yield efficiency by 38% and reducing production waste. This innovation is expected to lower costs for wound healing formulations in pharmaceutical and skincare sectors.
• Medterra CBD: Medterra introduced a CBG-enriched roll-on gel in late 2023, targeting post-operative wound recovery. The product, tested on a sample group of 300 patients, showed 34% faster recovery rates than placebo gels in minor wound scenarios.
• FAB CBD: FAB CBD entered the wound care category with a line of organic CBG salves and sprays, garnering 29% market share in the “natural first aid” product segment within six months of launch in North America.
• CBDistillery: CBDistillery reformulated its CBG tinctures in 2024 to enhance skin absorption, increasing topical efficiency by 36% in clinical patch tests. The new formulation is expected to lead to wider use in OTC Wound Healing Care products.

Report Coverage

The Cannabigerol (CBG) market report offers comprehensive coverage across several critical parameters including product innovation, therapeutic applications, consumer trends, and competitive landscape. The report highlights that over 51% of the market demand is currently tied to wellness and skincare applications, including Wound Healing Care. With 48% of global consumers showing interest in plant-derived topical alternatives, the role of CBG in both preventive and reactive skin treatment is emphasized.

Detailed segmentation data reveals that CBG Isolate and Full Spectrum Oils are dominating product preferences due to their compatibility with Wound Healing Care formulations. Additionally, the analysis shows that 40% of dermatologists and healthcare professionals are inclined to recommend CBG-based products, reflecting increasing trust in its efficacy. The report also includes profiles of 18 key companies, market share evaluations, R&D insights, and product launch case studies, providing investors and stakeholders a strategic roadmap to capitalize on the growing therapeutic cannabinoid space.